5th Jubilee Baltic Congress on Child Neurology was held on June 8-10 in Saint Petersburg. The Congress was attended not only by specialists from different regions of Russia and CIS countries, but also by specialists of an International Association of Neurologists. The participation of foreign high-class neurology experts raised a level of the event even higher and allowed Russian specialists to improve their professional skills. Every year this event brings together neurologists and physicians of different specialities: paediatricians, neurosurgeons, geneticists, recreation therapists, psychologists, psychiatrists, representatives of healthcare authorities, medical and social services as well as teachers and students of medical institutes. This year the congress was attended by more than 1,000 delegates, which also confirms the event’s status and high level of interest in problems of child neurology.
The congress was opened by Valentina Ivanovna Guzeva, Professor, Chief
Child Neurologist of the Russian Federation, Head of the Department of
Nervous Diseases of Saint Petersburg State Medical Paediatric
All main sections of paediatric neurology were represented in the scientific program of the congress. During the event an exhibition took place. The companies presented their latest innovations and achievements in terms of paediatric neurology. GEROPHARM, Group of Companies also presented its portfolio of products in neurology. The company is the sole manufacturer of the original drug Cortexin. Form of this drug containing 5 mg of Cortexin is specifically developed for treatment of children from the first days of their life to 5 years of age, as at this age they require a smaller dosage of medication. Cortexin is well known and widely used by neonatologists, paediatric neurologists, paediatricians in the treatment of the nervous system diseases, as one of the few neuroprotective drugs, not only effective but also safe without contraindications and adverse events. Generic drug Levetinol was also presented. It is a modern drug targeted for treatment of various forms of epilepsy. It shows higher efficiency and tolerability in comparison with other AEDs. Levetinol is used in monotherapy for the treatment of localized and generalized forms of the disease, as well as in the composition of the combined treatment.
GEROPHARM was the general partner of the congress and in collaboration with leading departments and research groups the company organized a satellite symposium addressing to the current problems of paediatric and adult neurology. This symposium was attended by more than 120 listeners. The fact that the symposium was opened by V.I. Guzeva, Chief Child Neurologist of the Russian Federation, gave the event a high profile. In her welcoming speech Valentina Ivanovna drew attention to the wide range of clinical problems covered by the symposium and expressed the wish that the company should successfully develop further and that this development should improve child healthcare.
In their speeches professor N.N. Zavadenko and professor E.A. Balakireva drew attention to the problem of the high prevalence of psychoverbal development delays, attention deficit/hyperactivity disorder (ADHD) and autism. In addition to scientific issues related to the need of correct diagnostics practical therapy issues were covered. Cortexin was named as the main drug used for treatment in almost all cases of associated psychoverbal development delays.
The important role of Cortexin in relieving super refractory status epilepticus was highlighted by professor P.N. Vlasov in his speech. He emphasized the fact that such conditions could probably involve specific pathological mechanisms that failed to respond to conventional treatments. In this case Cortexin can be a life-saving drug and this has to be taken into account.
I.O. Shchederkina, Head of the Neurology Department of Advisory Centre of Morozov Children’s City Clinical Hospital of the Health Department of the city of Moscow, Assistant Professor of the Department of Neurology, Neurosurgery and Genetics of Paediatric Department of the Pirogov Russian National Research Medical University, spoke about Levetinol use in epilepsy treatment. Based on a unique experience of 12 months of observations of patients receiving Levetinol, the author reported high rates of remission and overall effectiveness of the drug. I.O. Shchederkina particularly highlighted that the results had been achieved for serious and very serious patients. The author mentioned high safety and tolerability of the drug and possibility to use it especially by patients for which the use of conventional therapy was dangerous or contraindicated.
The Baltic Congress allowed its participants to acquire and share new knowledge and clinical experience, and companies were able to present their new products and technologies.